JL. you know the differences between the labels
WARNINGS AND PRECAUTIONS -----------------------
• In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy. (5.1)
• LOVAZA may increase levels of low-density lipoprotein (LDL). Monitor LDL levels periodically during therapy. (5.1)
• Use with caution in patients with known hypersensitivity to fish and/or shellfish. (5.2)
• There is a possible association between LOVAZA and more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first months of initiating therapy. (5.3)
Can you explain to me why you pay so much more than poster North for Vascepa. ?
The main reason I think I have a far lower co pay than you ( no where as good as North ) is that Kaiser has determined its cost effective for them to have me on Vascepa ....to reduce their risk of having to pay for most of a PCI .
Back back to your original argument .....competition . GV to be more expensive than G Lovaza . Doubt if it will be a huge difference . There is a Marine market for G Vascepa ...for all those who dont want to take statins or can not tolerate a higher dose of the statin they are on to control elevated LDL....but still need to lower very high TG's.
Hopefully it won't come to that . Singer will ride to the rescue ...in that we trust .
Kiwi
News 
Market Data 
Discover 
